6/27/2013

Metabolic imaging using 18F-FDG-PET/CT helps predict the overall survival of patients with castrate-resistant metastatic prostate cancer, according to a study published in The Journal of Nuclear Medicine. Data provided by the imaging method "may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies," researchers said.

Related Summaries